Effects of systemic chemotherapy.
Two groups of SJL mice (10 mice per group) were injected IV (tail vein) with live 105 AML cells on day 0. One group (AML, ■) received no treatment; the second group (AML plus chemotherapy, ▪) was treated with chemotherapy (chemo) as described in “Materials and methods.” (A) Flow cytometric analysis of AML and AML-plus-chemotherapy splenocytes on day 21 (1 week after the second dose of chemotherapy). In all panels, solid histograms represent the expression of the indicated markers by splenocytes. (B) AML and AML-plus-chemotherapy splenocytes were cultured at 2 ×105cells per well in U-bottomed 96-well plates coated with suboptimal dose (100 ng/mL) of anti-CD3 mAb 145-2C11 and the indicated amounts of plate-bound B7.2-IgG. Response to costimulation with anti-CD3 plus anti-CD28 (1 μg/mL) was used as positive control. Proliferation of responder cells was measured after 72 hours by the incorporation of3H thymidine (1 μCi per well) for the last 18 hours of incubation. Results are representative of 2 independent experiments and are shown as the mean ± SD of 8 cultures. (C) AML and AML-plus-chemotherapy splenocytes were cultured as described in panel B. IL-2 concentrations were determined in 24-hour tissue-culture supernatants. Results are representative of 2 independent experiments and are shown as the mean ± SD of 8 cultures.
